Targeting the c-MET with inhibitors such as PHA-665752 and ARQ197 (tivantinib) demonstrated significant responses in brain metastasis-derived cell lines in vivo, suggesting the potential of MET-targeted therapy in managing melanoma brain metastases and improving patient outcomes (121). This evidence concerns the gene MET and melanoma.